Clinical Trial Update: Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cetuximab with or without tivantinib in recurrent/metastatic head and neck squamous cell carcinoma; study completed with posted results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• tivantinib (tivantinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2018-12-19